Report

attention deficit hyperactivity market

Attention Deficit Hyperactivity Market by Drug Type (Stimulant and Non-stimulant), Demographic (Adult and Children), Distribution Channel (Retail Pharmacy and Hospital Pharmacy), and Geography – Global Forecast up to 2026

pages Pages: 81
tables Tables: 90
charts Charts: 60
country Regions/Countries: 4 / 10
compaines Companies: 10
enqhours Enquiry Hours: 10
  • Get Free 10% Customization in this Report

COVID - 19

Covid impact updated reports at special price

Attention deficit hyperactivity disorder is a disease of the brain, previously known as attention deficit disorder. It is one of the most general mental disorders affecting children as well as adults. Attention deficit hyperactivity disorder is when the patient has difficulty sitting still, focusing on tasks, and paying attention. The patient with this disorder acts without thinking. This disease can be diagnosed between the age of 6 and 12 years. The growing number of pre-term births of babies is a fueling factor for the attention deficit hyperactivity disorder market growth. The University of Maryland Medical Center (UMMC) predicts that 20% of prematurely born babies have this disorder. The rising trend of pregnant women of toxins such as alcohol, cigarette, and drugs result in children born with attention deficit hyperactivity disorder. Complementary and alternative therapies such as vitamins, special diets, minerals, and herbs may hamper the attention deficit hyperactivity disorder market growth during the forecast period. The Attention Deficit Hyperactivity Market is expected to grow at the rate of 8.4% CAGR by 2026.

Research Methodology:

The attention deficit hyperactivity disorder market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology and a unique balance of primary insights. The real-time valuation of the market is an integral part of our forecasting and market sizing methodology. Industry experts and our primary participants have helped to compile related aspects with accurate parametric estimations for a complete study. The primary participants share is given below:

Attention Deficit Hyperactivity Market

The Attention Deficit Hyperactivity Market is has been segmented on the basis of:              

Attention Deficit Hyperactivity Market based on Drug Type

  • Stimulant
  • Non-stimulant

 Attention Deficit Hyperactivity Market based on Demographic

  • Adult (Aged 18 and above)
  • Children

Attention Deficit Hyperactivity Market based on Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy

Attention Deficit Hyperactivity Market based on Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

The attention deficit hyperactivity market is bifurcated into stimulant and non-stimulant based on drug type. The stimulant drug type has a significant share in the attention deficit hyperactivity market. The major share is due to the huge demand for these drugs due to their effectiveness in treating attention deficit hyperactivity disorder symptoms. Ongoing clinical trials and government provision for the use of stimulants to treat mental health disorders are other factors driving the segment’s growth.

As per the demography, the attention deficit hyperactivity market is divided into adults and children. The adult segment is accounted for a substantial share in the market. This is due to the huge patient population, and it is considered that most of the adult population in the United States are affected by attention deficit hyperactivity.

According to the distribution channel, the channels are categorized into a retail pharmacy and a hospital pharmacy. Compared to hospital pharmacies, the retail pharmacy holds the maximum share in the market due to the rising number of prescriptions, increased inpatient care initiatives by retail pharmacies, and most patients prefer purchasing drugs from retail pharmacies.

In terms of the geography segment, the North American region holds a major position in the market share. The factors such as the presence of key players in the region and the rising number of collaborations are increasing market penetration. Moreover, the increase in product launches also enhances the market's growth in the region.

In addition, the increasing awareness among people worldwide about maintaining mental health is one of the key factors driving the market growth. The changes in the living style and value systems of people have affected the quality of birth. Additionally, the increasing use of preservatives and additives in children’s diets raises the number of attention deficit hyperactivity disorder cases among the age group of 4-17 years. Therefore, this is fueling the growth of the global market.

This report includes the key players of the attention deficit hyperactivity market: Eli Lilly & Company, Supernus Pharmaceuticals, Inc., Johnson & Johnson Services Inc, Hisamitsu Pharmaceutical Co., Inc Lupin Limited, NEOS Therapeutics Inc., Mallinckrodt Pharmaceuticals, and Impax Laboratories, LLC.

Henceforth, poor nutrition, infections, smoking, drinking, and substance abuse during pregnancy are the common reasons for the cause of attention deficit hyperactivity, where various therapeutics and drugs have a prominent role in the treatment. Moreover, this disorder is considered a social stigma since the emphasis on ADHD treatment has increased.

  • To provide an inclusive analysis on the attention deficit hyperactivity market by drug type, by age group, by distribution channel, and by region
  • To cater complete information on factors influencing market growth such as drivers, restraints, opportunities, and industry-specific restraints
  • To estimate the market size in key regions, which include North America, Europe, Asia Pacific, and the rest of the world
  • To register and evaluate competitive landscape mapping-product launches, technological advancements, mergers, and expansions
  1. Executive Summary
  2. Industry Outlook
    1. Industry Overview
    2. Industry Trends
  3. Market Snapshot
    1. Market Definition
    2. Market Outlook
      1. Porter Five Forces
    3. Related Markets
  4. Market characteristics
    1. Market Overview
    2. Market Segmentation
    3. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
    4. DRO - Impact Analysis
  5. Drug Type: Market Size & Analysis
    1. Overview
    2. Stimulant
    3. Non-stimulant
  6. Demographic: Market Size & Analysis
    1. Overview
    2. Adult (Aged 18 and above)
    3. Children
  7. Distribution Channel: Market Size & Analysis
    1. Overview
    2. Retail Pharmacy
    3. Hospital Pharmacy
  8. Geography: Market Size & Analysis
    1. Overview
    2. North America
    3. Europe
    4. Asia Pacific
    5. Rest of the World
  9. Competitive Landscape
    1. Competitor Comparison Analysis
    2. Market Developments
      1. Mergers and Acquisitions, Legal, Awards, Partnerships
      2. Product Launches and execution
  10. Vendor Profiles
    1. Eli Lilly & Company
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    2. Johnson & Johnson Services Inc
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    3. Lupin Limited
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    4. Mallinckrodt Pharmaceuticals
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    5. NEOS Therapeutics Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    6. Hisamitsu Pharmaceutical Co., Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    7. Impax Laboratories, LLC
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    8. Supernus Pharmaceuticals, Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    9. GlaxoSmithKline PLC
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    10. Purdue Pharma L.P
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
  11. Analyst Opinion
  12. Annexure
    1. Report Scope
    2. Market Definitions
    3. Research Methodology
      1. Data Collation and In-house Estimation
      2. Market Triangulation
      3. Forecasting
    4. Report Assumptions
    5. Declarations
    6. Stakeholders
    7. Abbreviations

TABLE 1.           GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 2.           GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR STIMULANT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 3.           GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR NON-STIMULANT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 4.           GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 5.           GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR ADULT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 6.           GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR CHILDREN, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 7.           GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 8.           GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR RETAIL PHARMACY, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 9.           GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 10.         NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 11.         NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 12.         NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 13.         NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 14.         U.S ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 15.         U.S ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 16.         U.S ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 17.         CANADA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 18.         CANADA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 19.         CANADA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 20.         EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 21.         EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 22.         EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 23.         EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 24.         GERMANY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 25.         GERMANY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 26.         GERMANY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 27.         U.K ATTENTION DEFICIT HYPERACTIVITY  MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 28.         U.K ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 29.         U.K ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 30.         FRANCE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 31.         FRANCE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 32.         FRANCE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 33.         ITALY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 34.         ITALY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 35.         ITALY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 36.         SPAIN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 37.         SPAIN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 38.         SPAIN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 39.         ROE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 40.         ROE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 41.         ROE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 42.         ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 43.         ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 44.         ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 45.         ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 46.         CHINA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 47.         CHINA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 48.         CHINA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 49.         INDIA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 50.         INDIA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 51.         INDIA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 52.         JAPAN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 53.         JAPAN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 54.         JAPAN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 55.         REST OF APAC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 56.         REST OF APAC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 57.         REST OF APAC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 58.         REST OF WORLD ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 59.         REST OF WORLD ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 60.         REST OF WORLD ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 61.         ELI LILLY & COMPANY: FINANCIALS     

TABLE 62.         ELI LILLY & COMPANY: PRODUCTS & SERVICES           

TABLE 63.         ELI LILLY & COMPANY: RECENT DEVELOPMENTS          

TABLE 64.         JOHNSON & JOHNSON SERVICES INC: FINANCIALS     

TABLE 65.         JOHNSON & JOHNSON SERVICES INC: PRODUCTS & SERVICES           

TABLE 66.         JOHNSON & JOHNSON SERVICES INC: RECENT DEVELOPMENTS          

TABLE 67.         LUPIN LIMITED: FINANCIALS   

TABLE 68.         LUPIN LIMITED: PRODUCTS & SERVICES         

TABLE 69.         LUPIN LIMITED: RECENT DEVELOPMENTS        

TABLE 70.         MALLINCKRODT PHARMACEUTICALS: FINANCIALS       

TABLE 71.         MALLINCKRODT PHARMACEUTICALS: PRODUCTS & SERVICES 

TABLE 72.         MALLINCKRODT PHARMACEUTICALS: RECENT DEVELOPMENTS

TABLE 73.         NEOS THERAPEUTICS INC.: FINANCIALS          

TABLE 74.         NEOS THERAPEUTICS INC.: PRODUCTS & SERVICES    

TABLE 75.         NEOS THERAPEUTICS INC.: RECENT DEVELOPMENTS  

TABLE 76.         HISAMITSU PHARMACEUTICAL CO., INC: FINANCIALS 

TABLE 77.         HISAMITSU PHARMACEUTICAL CO., INC: PRODUCTS & SERVICES        

TABLE 78.         HISAMITSU PHARMACEUTICAL CO., INC: RECENT DEVELOPMENTS      

TABLE 79.         IMPAX LABORATORIES, LLC: FINANCIALS        

TABLE 80.         IMPAX LABORATORIES, LLC: PRODUCTS & SERVICES  

TABLE 81.         IMPAX LABORATORIES, LLC: RECENT DEVELOPMENTS 

TABLE 82.         SUPERNUS PHARMACEUTICALS, INC: FINANCIALS       

TABLE 83.         SUPERNUS PHARMACEUTICALS, INC: PRODUCTS & SERVICES 

TABLE 84.         SUPERNUS PHARMACEUTICALS, INC: RECENT DEVELOPMENTS

TABLE 85.         GLAXOSMITHKLINE PLC: FINANCIALS  

TABLE 86.         GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES        

TABLE 87.         GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS       

TABLE 88.         PURDUE PHARMA L.P: FINANCIALS      

TABLE 89.         PURDUE PHARMA L.P: PRODUCTS & SERVICES

TABLE 90.         PURDUE PHARMA L.P: RECENT DEVELOPMENTS           

Research Framework

Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting
Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources

Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources

Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.

outicon

Attention Deficit Hyperactivity Market by Drug Type (Stimulant and Non-stimulant), Demographic (Adult and Children), Distribution Channel (Retail Pharmacy and Hospital Pharmacy), and Geography – Global Forecast up to 2026
Interested in this report?
Get your FREE sample now!

Select User License

$

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer 10% worth of FREE customization at the time of purchase

Speak to our analyst
Related Reports